Indaptus Therapeutics (INDP) News Today

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

$2.36

-0.16 (-6.35%)

(As of 04/19/2024 ET)

Source

Source	Headline
	HC Wainwright Analysts Cut Earnings Estimates for Indaptus Therapeutics, Inc. (NASDAQ:INDP) americanbankingnews.com - April 18 at 1:28 AM
	Indaptus Therapeutics, Inc. (NASDAQ:INDP) to Post Q1 2025 Earnings of ($0.38) Per Share, HC Wainwright Forecasts americanbankingnews.com - April 17 at 1:54 AM
	Buy Rating Affirmed for Indaptus Therapeutics Amidst Promising Clinical Advances and Potential Market Impact markets.businessinsider.com - April 16 at 8:09 AM
	Indaptus Therapeutics' (INDP) Buy Rating Reaffirmed at HC Wainwright americanbankingnews.com - April 16 at 4:46 AM
	Indaptus reveals immune-boosting cancer therapy data investing.com - April 12 at 10:19 PM
	Buy Rating for Indaptus Therapeutics: Promising Oncology Breakthrough with Decoy20 Platform markets.businessinsider.com - April 12 at 10:19 PM
	Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting globenewswire.com - April 11 at 7:30 AM
	Armaguard rebuffs $26m cash lifeline msn.com - March 28 at 9:00 PM
	Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference finance.yahoo.com - March 28 at 9:38 AM
	Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting globenewswire.com - March 25 at 8:30 AM
	Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024 finance.yahoo.com - March 18 at 8:44 AM
	Indaptus Dives on Quarterly Results msn.com - March 13 at 12:42 PM
	Indaptus Therapeutics: Q4 Earnings Insights benzinga.com - March 13 at 12:42 PM
	Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update globenewswire.com - March 13 at 7:30 AM
	Indaptus Reports Positive Decoy20 Results, To Advance To Multi-dosing; Stock Up In Pre-market markets.businessinsider.com - March 4 at 10:19 AM
	Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort globenewswire.com - March 4 at 7:30 AM
	Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort globenewswire.com - March 4 at 7:30 AM
	Indaptus Therapeutics Stock (NASDAQ:INDP) Insider Trades benzinga.com - February 25 at 12:26 AM
	Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference finance.yahoo.com - February 15 at 8:19 AM
	Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels finance.yahoo.com - February 8 at 10:17 AM
	European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology finance.yahoo.com - January 4 at 10:08 AM
	Indaptus Therapeutics, Inc. (INDP) stock forecast and price target finance.yahoo.com - December 22 at 11:55 PM
	Indaptus Therapeutics (INDP) Price Target Increased by 25.00% to 10.20 msn.com - November 27 at 9:51 AM
	Analysts Conflicted on These Healthcare Names: Ventyx Biosciences (VTYX) and Indaptus Therapeutics (INDP) markets.businessinsider.com - November 7 at 11:10 PM
	Indaptus Therapeutics GAAP EPS of -$0.47 beats by $0.05 msn.com - November 6 at 8:29 PM
	Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update finance.yahoo.com - November 6 at 8:29 PM
	Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study finance.yahoo.com - November 6 at 10:28 AM
	Indaptus Therapeutics: Promising Phase 1 Results and Optimistic Valuation Bolster Buy Rating markets.businessinsider.com - November 4 at 5:42 PM
	Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting finance.yahoo.com - October 31 at 12:49 PM
	Here's Why We're Watching Indaptus Therapeutics' (NASDAQ:INDP) Cash Burn Situation finance.yahoo.com - October 9 at 1:47 PM
	Indaptus Therapeutics to Present at the LD Micro Main Event XVI finance.yahoo.com - September 27 at 10:30 AM
	Registration Is Now Open For Tribe Public’s Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics’ CEO On Friday, September 29, 2023 finance.yahoo.com - September 26 at 11:35 AM
	Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20 finance.yahoo.com - September 19 at 8:47 AM
	Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference finance.yahoo.com - September 6 at 8:12 AM
	Favourable Signals For Indaptus Therapeutics: Numerous Insiders Acquired Stock finance.yahoo.com - August 29 at 10:21 AM
	Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update finance.yahoo.com - August 14 at 8:26 AM
	Maxim Group Remains a Buy on Indaptus Therapeutics (INDP) markets.businessinsider.com - August 11 at 3:58 PM
	Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20 finance.yahoo.com - August 10 at 1:47 PM
	Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer finance.yahoo.com - August 7 at 10:01 AM
	Indaptus Therapeutics to Present at the Jefferies Healthcare Conference 2023 finance.yahoo.com - May 31 at 12:41 PM
	Indaptus Therapeutics to Present at the Jefferies Healthcare Conference 2023 finance.yahoo.com - May 31 at 12:41 PM
	Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform finance.yahoo.com - May 9 at 8:23 AM
	What 4 Analyst Ratings Have To Say About Indaptus Therapeutics markets.businessinsider.com - May 4 at 5:24 PM
	HC Wainwright & Co. Reiterates Indaptus Therapeutics (INDP) Buy Recommendation msn.com - May 4 at 12:23 PM
	We Think Indaptus Therapeutics (NASDAQ:INDP) Needs To Drive Business Growth Carefully finance.yahoo.com - May 2 at 8:58 AM
	Indaptus Therapeutics' Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit benzinga.com - May 1 at 9:27 AM
	Indaptus Therapeutics’ Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit finance.yahoo.com - May 1 at 9:27 AM
	Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023 finance.yahoo.com - April 20 at 4:15 PM
	Indaptus Therapeutics Says Antitumor Platform Demonstrates Preclinical Efficacy Across Cancer Indications msn.com - April 19 at 1:05 PM
	Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023 finance.yahoo.com - April 19 at 1:05 PM

Get Indaptus Therapeutics News Delivered to You Automatically

Secret Bull Market Starts in This Unusual Sector (Ad)

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

INDP Media Mentions By Week

INDP Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

INDP
News Sentiment
▼
0.07

0.52
▲
Average
Medical
News Sentiment

INDP News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

INDP Articles
This Week
▼
13

1
▲
INDP Articles
Average Week

Get Indaptus Therapeutics News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (NASDAQ:INDP) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Indaptus Therapeutics (INDP) News Today

INDP Media Mentions By Week

INDP Media Sentiment

INDP News Coverage

Related Companies and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info